United Therapeutics Corporation Increase (Decrease) in Other Operating Assets and Liabilities, Net
United Therapeutics Corporation (UTHR) reported Increase (Decrease) in Other Operating Assets and Liabilities, Net of $77.10 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet · last filed 2026-08-05
- United Therapeutics Corporation increase (decrease) in other operating assets and liabilities, net for the quarter ending 2026-06-30 was $104.10M, a 43.55% decline year-over-year.
- United Therapeutics Corporation increase (decrease) in other operating assets and liabilities, net for the quarter ending 2026-03-31 was -$27.00M.
- United Therapeutics Corporation increase (decrease) in other operating assets and liabilities, net for the quarter ending 2025-12-31 was $98.20M.
- United Therapeutics Corporation increase (decrease) in other operating assets and liabilities, net for the quarter ending 2025-09-30 was -$67.20M.
- United Therapeutics Corporation increase (decrease) in other operating assets and liabilities, net for fiscal 2025 was $80.90M.
- United Therapeutics Corporation increase (decrease) in other operating assets and liabilities, net for fiscal 2024 was -$8.50M, a 146.20% decline from fiscal 2023.
- United Therapeutics Corporation increase (decrease) in other operating assets and liabilities, net for fiscal 2023 was $18.40M, a 87.78% decline from fiscal 2022.
- United Therapeutics Corporation increase (decrease) in other operating assets and liabilities, net for fiscal 2022 was $150.60M, a 33.39% increase from fiscal 2021.
| Period end | Increase (Decrease) in Other Operating Assets and Liabilities, Net 3 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 3 month as first filed | Increase (Decrease) in Other Operating Assets and Liabilities, Net 6 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 6 month as first filed | Increase (Decrease) in Other Operating Assets and Liabilities, Net 9 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 9 month as first filed | Increase (Decrease) in Other Operating Assets and Liabilities, Net 12 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $104.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $77.10M 10-Q · filed 2026-08-05 | $175.30M derived: sum of 3 quarters · filed 2026-08-05 | $108.10M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | -$27.00M 10-Q · filed 2026-05-06 | $71.20M derived: sum of 2 quarters · filed 2026-05-06 | $4.00M derived: sum of 3 quarters · filed 2026-05-06 | $188.40M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $98.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $31.00M derived: sum of 2 quarters · filed 2026-02-25 | $215.40M derived: sum of 3 quarters · filed 2026-08-05 | $80.90M 10-K · filed 2026-02-25 | ||||
| 2025-09-30 | -$67.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $117.20M derived: sum of 2 quarters · filed 2026-08-05 | -$17.30M 10-Q · filed 2025-10-29 | -$44.30M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $184.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $49.90M 10-Q · filed 2026-08-05 | $22.90M derived: sum of 3 quarters · filed 2026-08-05 | -$19.50M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | -$134.50M 10-Q · filed 2026-05-06 | -$161.50M derived: sum of 2 quarters · filed 2026-05-06 | -$203.90M derived: sum of 3 quarters · filed 2026-05-06 | -$67.50M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | -$27.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$69.40M derived: sum of 2 quarters · filed 2026-02-25 | $67.00M derived: sum of 3 quarters · filed 2026-02-25 | -$8.50M 10-K · filed 2026-02-25 | $55.60M 10-K · filed 2025-02-26 | |||
| 2024-09-30 | -$42.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-29 | $94.00M derived: sum of 2 quarters · filed 2025-10-29 | $18.50M 10-Q · filed 2025-10-29 | -$4.60M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-06-30 | $136.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-30 | $60.90M 10-Q · filed 2025-07-30 | $37.80M derived: sum of 3 quarters · filed 2026-02-25 | $42.10M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2024-03-31 | -$75.50M 10-Q · filed 2025-04-30 | -$98.60M derived: sum of 2 quarters · filed 2026-02-25 | -$94.30M derived: sum of 3 quarters · filed 2026-02-25 | -$16.10M derived: sum of 4 quarters · filed 2026-02-25 | ||||
| 2023-12-31 | -$23.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$18.80M derived: sum of 2 quarters · filed 2026-02-25 | $59.40M derived: sum of 3 quarters · filed 2026-02-25 | $18.40M 10-K · filed 2026-02-25 | $82.80M 10-K · filed 2024-02-21 | |||
| 2023-09-30 | $4.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | $82.50M derived: sum of 2 quarters · filed 2024-10-30 | $41.50M 10-Q · filed 2024-10-30 | $135.80M derived: sum of 4 quarters · filed 2025-02-26 | ||||
| 2023-06-30 | $78.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | $37.20M 10-Q · filed 2024-07-31 | $131.50M derived: sum of 3 quarters · filed 2025-02-26 | $102.20M derived: sum of 4 quarters · filed 2025-02-26 | ||||
| 2023-03-31 | -$41.00M 10-Q · filed 2024-05-01 | $53.30M derived: sum of 2 quarters · filed 2025-02-26 | $24.00M derived: sum of 3 quarters · filed 2025-02-26 | $154.50M derived: sum of 4 quarters · filed 2025-02-26 | ||||
| 2022-12-31 | $94.30M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $65.00M derived: sum of 2 quarters · filed 2025-02-26 | $195.50M derived: sum of 3 quarters · filed 2025-02-26 | $150.60M 10-K · filed 2025-02-26 | ||||
| 2022-09-30 | -$29.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $101.20M derived: sum of 2 quarters · filed 2023-11-01 | $56.30M 10-Q · filed 2023-11-01 | $68.90M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2022-06-30 | $130.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $85.60M 10-Q · filed 2023-08-02 | $98.20M derived: sum of 3 quarters · filed 2024-02-21 | $116.80M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2022-03-31 | -$44.90M 10-Q · filed 2023-05-03 | -$32.30M derived: sum of 2 quarters · filed 2024-02-21 | -$13.70M derived: sum of 3 quarters · filed 2024-02-21 | $57.80M derived: sum of 4 quarters · filed 2024-02-21 | ||||
| 2021-12-31 | $12.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $31.20M derived: sum of 2 quarters · filed 2024-02-21 | $102.70M derived: sum of 3 quarters · filed 2024-02-21 | $112.90M 10-K · filed 2024-02-21 | ||||
| 2021-09-30 | $18.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | $90.10M derived: sum of 2 quarters · filed 2022-11-02 | $100.30M 10-Q · filed 2022-11-02 | $144.40M derived: sum of 4 quarters · filed 2023-02-22 | ||||
| 2021-06-30 | $71.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $81.70M 10-Q · filed 2022-08-03 | $125.80M derived: sum of 3 quarters · filed 2023-02-22 | $104.60M derived: sum of 4 quarters · filed 2023-02-22 | ||||
| 2021-03-31 | $10.20M 10-Q · filed 2022-05-04 | $54.30M derived: sum of 2 quarters · filed 2023-02-22 | $33.10M derived: sum of 3 quarters · filed 2023-02-22 | $53.90M derived: sum of 4 quarters · filed 2023-02-22 | ||||
| 2020-12-31 | $44.10M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $22.90M derived: sum of 2 quarters · filed 2023-02-22 | $43.70M derived: sum of 3 quarters · filed 2023-02-22 | -$20.20M 10-K · filed 2023-02-22 | -$16.80M 10-K · filed 2021-02-24 | |||
| 2020-09-30 | -$21.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | -$400.00K derived: sum of 2 quarters · filed 2021-11-03 | -$64.30M 10-Q · filed 2021-11-03 | -$60.80M 10-Q · filed 2020-10-28 | -$55.40M derived: sum of 4 quarters · filed 2022-02-24 | |||
| 2020-06-30 | $20.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | -$43.10M 10-Q · filed 2021-08-04 | -$41.90M 10-Q · filed 2020-07-29 | -$34.20M derived: sum of 3 quarters · filed 2022-02-24 | -$29.40M derived: sum of 4 quarters · filed 2022-02-24 | |||
| 2020-03-31 | -$63.90M 10-Q · filed 2021-05-05 | -$61.90M 10-Q · filed 2020-04-29 | -$55.00M derived: sum of 2 quarters · filed 2022-02-24 | -$50.20M derived: sum of 3 quarters · filed 2022-02-24 | -$33.60M derived: sum of 4 quarters · filed 2022-02-24 | |||
| 2019-12-31 | $8.90M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $13.70M derived: sum of 2 quarters · filed 2022-02-24 | $30.30M derived: sum of 3 quarters · filed 2022-02-24 | $199.30M 10-K · filed 2022-02-24 | $201.90M 10-K · filed 2020-02-26 | |||
| 2019-09-30 | $4.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-28 | $21.40M derived: sum of 2 quarters · filed 2020-10-28 | $190.40M 10-Q · filed 2020-10-28 | $233.80M derived: sum of 4 quarters · filed 2021-02-24 | ||||
| 2019-06-30 | $16.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-29 | $185.60M 10-Q · filed 2020-07-29 | $229.00M derived: sum of 3 quarters · filed 2021-02-24 | $191.10M derived: sum of 4 quarters · filed 2021-02-24 | ||||
| 2019-03-31 | $169.00M 10-Q · filed 2020-04-29 | $212.40M derived: sum of 2 quarters · filed 2021-02-24 | $174.50M derived: sum of 3 quarters · filed 2021-02-24 | $174.40M derived: sum of 4 quarters · filed 2021-02-24 | ||||
| 2018-12-31 | $43.40M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $5.50M derived: sum of 2 quarters · filed 2021-02-24 | $5.40M derived: sum of 3 quarters · filed 2021-02-24 | -$4.70M 10-K · filed 2021-02-24 | ||||
| 2018-09-30 | -$37.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | -$38.00M derived: sum of 2 quarters · filed 2019-10-30 | -$48.10M 10-Q · filed 2019-10-30 | -$15.10M 10-Q · filed 2018-10-31 | -$38.80M derived: sum of 4 quarters · filed 2020-02-26 | |||
| 2018-06-30 | -$100.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | -$10.20M 10-Q · filed 2019-07-31 | -$900.00K derived: sum of 3 quarters · filed 2020-02-26 | $42.30M derived: sum of 4 quarters · filed 2020-02-26 | ||||
| 2018-03-31 | -$10.10M 10-Q · filed 2019-05-01 | -$800.00K derived: sum of 2 quarters · filed 2020-02-26 | $42.40M derived: sum of 3 quarters · filed 2020-02-26 | $105.10M derived: sum of 4 quarters · filed 2020-02-26 | ||||
| 2017-12-31 | $9.30M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | $52.50M derived: sum of 2 quarters · filed 2020-02-26 | $115.20M derived: sum of 3 quarters · filed 2020-02-26 | $61.40M 10-K · filed 2020-02-26 | ||||
| 2017-09-30 | $43.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-31 | $105.90M derived: sum of 2 quarters · filed 2018-10-31 | $52.10M 10-Q · filed 2018-10-31 | $102.90M derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2017-06-30 | $62.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-01 | $8.90M 10-Q · filed 2018-08-01 | $59.70M derived: sum of 3 quarters · filed 2019-02-27 | $54.40M derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2017-03-31 | -$53.80M 10-Q · filed 2018-05-02 | -$3.00M derived: sum of 2 quarters · filed 2019-02-27 | -$8.30M derived: sum of 3 quarters · filed 2019-02-27 | $55.40M derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2016-12-31 | $50.80M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | $45.50M derived: sum of 2 quarters · filed 2019-02-27 | $109.20M derived: sum of 3 quarters · filed 2019-02-27 | $71.80M 10-K · filed 2019-02-27 | ||||
| 2016-09-30 | -$5.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-25 | $58.40M derived: sum of 2 quarters · filed 2017-10-25 | $21.00M 10-Q · filed 2017-10-25 | $200.10M derived: sum of 4 quarters · filed 2018-02-21 | ||||
| 2016-06-30 | $63.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-07-27 | $26.30M 10-Q · filed 2017-07-27 | $205.40M derived: sum of 3 quarters · filed 2018-02-21 | -$15.90M derived: sum of 4 quarters · filed 2018-02-21 | ||||
| 2016-03-31 | -$37.40M 10-Q · filed 2017-04-26 | $141.70M derived: sum of 2 quarters · filed 2018-02-21 | -$79.60M derived: sum of 3 quarters · filed 2018-02-21 | $25.40M derived: sum of 4 quarters · filed 2018-02-21 | ||||
| 2015-12-31 | $179.10M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-21 | -$42.20M derived: sum of 2 quarters · filed 2018-02-21 | $62.80M derived: sum of 3 quarters · filed 2018-02-21 | $181.80M 10-K · filed 2018-02-21 | $181.82M 10-K · filed 2016-02-25 | |||
| 2015-09-30 | -$221.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-10-27 | -$116.30M derived: sum of 2 quarters · filed 2016-10-27 | $2.70M 10-Q · filed 2016-10-27 | $2.75M 10-Q · filed 2015-10-27 | $1.05M derived: sum of 4 quarters · filed 2017-02-22 | |||
| 2015-06-30 | $105.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-07-28 | $224.00M 10-Q · filed 2016-07-28 | $224.17M 10-Q · filed 2015-07-28 | $222.35M derived: sum of 3 quarters · filed 2017-02-22 | $296.33M derived: sum of 4 quarters · filed 2017-02-22 | |||
| 2015-03-31 | $119.00M 10-Q · filed 2016-04-28 | $119.21M 10-Q · filed 2015-04-28 | $117.35M derived: sum of 2 quarters · filed 2017-02-22 | $191.33M derived: sum of 3 quarters · filed 2017-02-22 | $281.30M derived: sum of 4 quarters · filed 2017-02-22 | |||
| 2014-12-31 | -$1.65M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-22 | $72.33M derived: sum of 2 quarters · filed 2017-02-22 | $162.30M derived: sum of 3 quarters · filed 2017-02-22 | $137.00M 10-K · filed 2017-02-22 | $136.97M 10-K · filed 2016-02-25 | |||
| 2014-09-30 | $73.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-10-27 | $163.94M derived: sum of 2 quarters · filed 2015-10-27 | $138.65M 10-Q · filed 2015-10-27 | |||||
| 2014-06-30 | $89.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-07-28 | $64.67M 10-Q · filed 2015-07-28 | ||||||
| 2014-03-31 | -$25.30M 10-Q · filed 2015-04-28 | |||||||
| 2013-12-31 | $97.41M 10-K · filed 2016-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |